For decades, people diagnosed with CLL or SLL have often faced the reality of long-term or even lifelong cancer treatments, as these slow-growing cancers tend to recur frequently, requiring additional ...

We searched the electronic database for patients with CLL or SLL who presented to The University of Texas M.D. Anderson Cancer Center (Houston, TX) between 1985 and 2005. We reviewed patient records ...

Jaypirca is approved for CLL/SLL patients previously treated with covalent BTK inhibitors, offering a new treatment option. The BRUIN-CLL-321 trial showed Jaypirca improved progression-free survival ...

Liso-cel therapy significantly improves response rates and survival outcomes in relapsed/refractory CLL/SLL patients compared to standard-of-care treatments. The TRANSCEND CLL 004 trial showed a 52.5% ...

There is no cure for CLL or SLL, but treatment can put the cancer into remission, where there are no signs of active disease. Recurrent or relapsed CLL or SLL is when you have had CLL or SLL that went ...

Pirtobrutinib showed an 80% reduction in PFS compared with BendaR in treatment-naïve CLL/SLL patients, indicating its potential as a first-line therapy. The trial demonstrated pirtobrutinib's superior ...

Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...

Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...

Treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) looks almost nothing like it did a decade ago, which is welcome news for patients. Today, targeted medications ...

SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that ...

Eli Lilly and Co (NYSE:LLY) on Monday shared topline results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval ...